{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:01:29Z","timestamp":1792551689707,"version":"4.5.0"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejca.2024.115152","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:01:11Z","timestamp":1732838471000},"page":"115152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024"],"prefix":"10.1016","volume":"215","author":[{"given":"Claus","family":"Garbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Brochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kelleners-Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilios","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"Van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115152_bib1","unstructured":"Howick J.C.I., Glasziou P., Greenhalgh T., Heneghan C., Liberati A., et al. In: Group OLoEW, editor The Oxford Levels of Evidence 2: Oxford Center for Evifdence-Based Medicine https:\/\/wwwcebmnet\/indexaspx?o=5653 Access Date: 23 April 2019."},{"key":"10.1016\/j.ejca.2024.115152_bib2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.115152_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","article-title":"Diagnosis and treatment of melanoma: european consensus-based interdisciplinary guideline","volume":"46","author":"Garbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CMR.0b013e3282f05039","article-title":"Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma","volume":"17","author":"Garbe","year":"2007","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0b013e3282f702bf","article-title":"Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting","volume":"18","author":"Garbe","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib6","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2011.13320","article-title":"Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma","author":"Dummer","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ejca.2024.115152_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CMR.0b013e3282f0c893","article-title":"Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma","volume":"18","author":"Garbe","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised U.K. guidelines for the management of cutaneous melanoma 2010","volume":"163","author":"Marsden","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib9","first-page":"325","article-title":"Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report","volume":"17","author":"Saiag","year":"2007","journal-title":"Eur J Dermatol: EJD"},{"key":"10.1016\/j.ejca.2024.115152_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2021.04.029","article-title":"Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036","volume":"152","author":"Garbe","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.09.044","article-title":"Cutaneous melanoma attributable to UVR exposure in Denmark and Germany","volume":"159","author":"Keim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","article-title":"Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib16","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., World Health Organization., International Agency for Research on Cancer. Solar and ultraviolet radiation: IARC;Distributed for the International Agency for Research on Cancer by the Secretariat of the World Health Organization; 1992."},{"key":"10.1016\/j.ejca.2024.115152_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1470-2045(09)70213-X","article-title":"A review of human carcinogens--part D: radiation","volume":"10","author":"El Ghissassi","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114074","article-title":"Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them","volume":"204","author":"Garbe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib19","unstructured":"Agents IWGotEoC-p, Organization WH, Cancer IAfRo. Sunscreens: International Agency for Research on Cancer; 2001."},{"key":"10.1016\/j.ejca.2024.115152_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","article-title":"Reduced melanoma after regular sunscreen use: randomized trial follow-up","volume":"29","author":"Green","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/1097-0215(20001201)88:5<838::AID-IJC25>3.0.CO;2-X","article-title":"An international evaluation of the cancer-preventive potential of sunscreens","volume":"88","author":"Vainio","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.22745","article-title":"Sunscreen use and increased duration of intentional sun exposure: still a burning issue","volume":"121","author":"Autier","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/ijc.22453","article-title":"The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review","volume":"120","author":"Green","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmjopen-2019-034388","article-title":"Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study","volume":"10","author":"Gordon","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2024.115152_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ypmed.2016.10.005","article-title":"Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure","volume":"93","author":"Pil","year":"2016","journal-title":"Prev Med"},{"key":"10.1016\/j.ejca.2024.115152_bib26","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA: a Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.115152_bib27","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0959-8049(03)00325-3","article-title":"Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas","volume":"39","author":"Spatz","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.0303-6987.2006.00452.x","article-title":"The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma","volume":"33","author":"Scolyer","year":"2006","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejca.2024.115152_bib29","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2011.38.8561","article-title":"Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib30","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2011.38.0584","article-title":"Superior outcome of women with stage I\/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials","volume":"30","author":"Joosse","year":"2012","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib31","first-page":"392","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg (Chic, Ill: 1960)"},{"key":"10.1016\/j.ejca.2024.115152_bib32","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib33","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III melanoma according to american joint committee on cancer version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pathol.2023.11.004","article-title":"Prognostic and predictive biomarkers in melanoma","volume":"56","author":"Maher","year":"2024","journal-title":"Pathology"},{"key":"10.1016\/j.ejca.2024.115152_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjd.15803","article-title":"Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients","volume":"178","author":"Teramoto","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/bjd\/ljad195","article-title":"Predictors of sentinel lymph node metastasis in very thin invasive melanomas","volume":"189","author":"Kakish","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjd.21274","article-title":"Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1\u200a578\u200a482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3)","volume":"187","author":"Di Carlo","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jnci\/djy086","article-title":"Primary melanoma histologic subtype: impact on survival and response to therapy","volume":"111","author":"Lattanzi","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115152_bib39","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jnci\/djz034","article-title":"Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers","volume":"111","author":"Dessinioti","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115152_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/jdv.15194","article-title":"Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry","volume":"33","author":"Gassenmaier","year":"2019","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ejca.2024.115152_bib41","article-title":"Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma","volume":"7","author":"Dinnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2024.115152_bib42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPWSDDHLLW40WI","article-title":"Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis","volume":"140","author":"Hall","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2024.115152_bib43","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ejso.2017.02.009","article-title":"Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma","volume":"43","author":"Oude Ophuis","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/CMR.0000000000000161","article-title":"Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma","volume":"25","author":"Bohelay","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib45","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ejso.2020.12.007","article-title":"The value of lymph node ultrasound and whole body (18)F-FDG PET\/CT in stage IIB\/C melanoma patients prior to SLNB","volume":"47","author":"Stahlie","year":"2021","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib46","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1200\/JCO.2008.19.0033","article-title":"Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?","volume":"27","author":"Voit","year":"2009","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib47","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib49","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib50","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: a National Observational Cohort Study of 25\u00a0720 Patients With Stage IA to IV Melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib51","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.ejso.2021.06.011","article-title":"Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients","volume":"47","author":"Helvind","year":"2021","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/archderm.141.4.434","article-title":"First prospective study of the recognition process of melanoma in dermatological practice","volume":"141","author":"Gachon","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mjd.2003.216","article-title":"Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection","volume":"48","author":"Chamberlain","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.134.1.103-a","article-title":"Bonerandi JJ. The \u2018ugly duckling\u2019 sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening","volume":"134","author":"Grob","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(02)00679-4","article-title":"Diagnostic accuracy of dermoscopy","volume":"3","author":"Kittler","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00008390-199602000-00008","article-title":"A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma","volume":"6","author":"Menzies","year":"1996","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0190-9622(94)70061-3","article-title":"The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions","volume":"30","author":"Nachbar","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1365-2133.2011.10621.x","article-title":"Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma","volume":"165","author":"Argenziano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib59","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2003.281","article-title":"Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet","volume":"48","author":"Argenziano","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamadermatol.2017.6447","article-title":"Accuracy of dermoscopic criteria for the diagnosis of melanoma in situ","volume":"154","author":"Lallas","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115152_bib61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.142.9.1113","article-title":"Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging","volume":"142","author":"Kittler","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib62","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archderm.144.9.1120","article-title":"Dermoscopic evaluation of amelanotic and hypomelanotic melanoma","volume":"144","author":"Menzies","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1346-8138.2010.01140.x","article-title":"Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma","volume":"38","author":"Moloney","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib64","first-page":"91","article-title":"Dermoscopic features of difficult melanoma","volume":"33","author":"Pizzichetta","year":"2007","journal-title":"Dermatol Surg: Publ Am Soc Dermatol Surg [Et al]"},{"key":"10.1016\/j.ejca.2024.115152_bib65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archdermatol.2011.136","article-title":"Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions","volume":"147","author":"Koga","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000372-198911020-00003","article-title":"Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics","volume":"11","author":"Saida","year":"1989","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ejca.2024.115152_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0738-081X(02)00219-5","article-title":"Dermoscopy for acral pigmented skin lesions","volume":"20","author":"Saida","year":"2002","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1346-8138.2010.01174.x","article-title":"Key points in dermoscopic differentiation between early acral melanoma and acral nevus","volume":"38","author":"Saida","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib69","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archderm.142.9.1123","article-title":"Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy","volume":"142","author":"Altamura","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0738-081X(02)00221-3","article-title":"Dermatoscopy for facial pigmented skin lesions","volume":"20","author":"Stolz","year":"2002","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0190-9622(00)90005-7","article-title":"Improvement of early recognition of lentigo maligna using dermatoscopy","volume":"42","author":"Schiffner","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2133.2012.10932.x","article-title":"Dermoscopy of lentigo maligna melanoma: report of 125 cases","volume":"167","author":"Pralong","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib73","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archderm.138.10.1327","article-title":"Dermoscopic examination of nail pigmentation","volume":"138","author":"Ronger","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib74","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archdermatol.2011.155","article-title":"Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS)","volume":"147","author":"Blum","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115152_bib75","article-title":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms","volume":"3","author":"Onkologie","year":"2018","journal-title":"Langversion"},{"issue":"6","key":"10.1016\/j.ejca.2024.115152_bib76","first-page":"1","article-title":"Malignant melanoma S3-guideline \"diagnosis, therapy and follow-up of melanoma\"","volume":"11","author":"Pflugfelder","year":"2013","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2024.115152_bib77","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/archderm.144.12.1618","article-title":"The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus","volume":"144","author":"Braun","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1346-8138.2010.01175.x","article-title":"Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia","volume":"38","author":"Koga","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib79","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2133.2009.09594.x","article-title":"Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population","volume":"162","author":"Phan","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib80","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/bjd.14045","article-title":"The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma","volume":"173","author":"Lallas","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib81","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.19759","article-title":"Total body photography for the diagnosis of cutaneous melanoma in adults: a systematic review and meta-analysis","volume":"185","author":"Ji-Xu","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib82","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jdv.12032","article-title":"Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society","volume":"27","author":"Salerni","year":"2013","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ejca.2024.115152_bib83","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjd.13148","article-title":"Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study","volume":"171","author":"Pellacani","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib84","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2016.1188","article-title":"Clinical indications for use of reflectance confocal microscopy for skin cancer diagnosis","volume":"152","author":"Borsari","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib85","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12678","article-title":"Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions","volume":"170","author":"Alarcon","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib86","article-title":"Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults","volume":"12","author":"Dinnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2024.115152_bib87","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamadermatol.2022.1570","article-title":"Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma: a randomized clinical trial","volume":"158","author":"Pellacani","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib88","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2017.3114","article-title":"Correlation of handheld reflectance confocal microscopy with radial video mosaicing for margin mapping of lentigo maligna and lentigo maligna melanoma","volume":"153","author":"Yelamos","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib89","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/bjd.13121","article-title":"Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety","volume":"171","author":"Malvehy","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115152_bib90","doi-asserted-by":"crossref","first-page":"512","DOI":"10.25251\/skin.5.5.9","article-title":"Non-invasive detection of genomic atypia increases real-world NPV and PPV of the melanoma diagnostic pathway and reduces biopsy burden","volume":"5","author":"Skelsey","year":"2021","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.ejca.2024.115152_bib91","doi-asserted-by":"crossref","unstructured":"I.M.N. Thomsen I.M. Heerfordt K.E. Karmisholt M. Mogensen Detection of cutaneous malignant melanoma by tape stripping of pigmented skin lesions - A systematic review Ski Res Technol: J Int Soc Bioeng Ski (ISBS) Int Soc Digit Imaging Ski (ISDIS) Int Soc Ski Imaging (ISSI) 29 2023 e13286.","DOI":"10.1111\/srt.13286"},{"key":"10.1016\/j.ejca.2024.115152_bib92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2021.06.049","article-title":"Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts","volume":"156","author":"Haggenm\u00fcller","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib93","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2023.0905","article-title":"Assessment of diagnostic performance of dermatologists cooperating with a convolutional neural network in a prospective clinical study: human with machine","volume":"159","author":"Winkler","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib94","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2589-7500(23)00130-9","article-title":"Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial","volume":"5","author":"Menzies","year":"2023","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.ejca.2024.115152_bib95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jdv.19521","article-title":"Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease","volume":"38","author":"Sangers","year":"2024","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"12","key":"10.1016\/j.ejca.2024.115152_bib96","article-title":"Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults","author":"Ferrante di Ruffano","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2024.115152_bib97","first-page":"m127","article-title":"Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies","volume":"368","author":"Freeman","year":"2020","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.ejca.2024.115152_bib98","first-page":"690","article-title":"Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice","volume":"9","author":"Garbe","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2024.115152_bib99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1053\/sonc.2002.34116","article-title":"Pathologic staging of melanoma","volume":"29","author":"Ruiter","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cps.2021.05.003","article-title":"Histopathologic and molecular diagnosis of melanoma","volume":"48","author":"Wilson","year":"2021","journal-title":"Clin Plast Surg"},{"key":"10.1016\/j.ejca.2024.115152_bib101","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cup.12867","article-title":"Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001-2015)","volume":"44","author":"Kim","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejca.2024.115152_bib102","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2023.6417","article-title":"Immunohistochemistry for diagnosing melanoma in older adults","author":"Ojukwu","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/CMR.0000000000000312","article-title":"Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the Canton of Zurich, Switzerland","volume":"27","author":"Minini","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib104","article-title":"Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia","author":"Matas-Nadal","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjd.15803","article-title":"Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients","volume":"178","author":"Teramoto","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib106","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.115152_bib107","series-title":"WHO Classification of Skin Tumours","first-page":"66","article-title":"Melanocytic tumour classification and the pathway concept of melanoma pathogenesis","author":"Elder","year":"2018"},{"key":"10.1016\/j.ejca.2024.115152_bib108","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamadermatol.2018.0288","article-title":"Association of skin examination behaviors and thinner nodular vs superficial spreading melanoma at diagnosis","volume":"154","author":"Dessinioti","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib109","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djz034","article-title":"Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers","author":"Dessinioti","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115152_bib110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib111","series-title":"WHO Classification of Skin Tumours","first-page":"105","article-title":"Desmoplastic melanoma","author":"Scolyer","year":"2018"},{"issue":"3","key":"10.1016\/j.ejca.2024.115152_bib112","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00877248","article-title":"Phase II study of didemnin B in advanced colorectal cancer","volume":"10","author":"Jones","year":"1992","journal-title":"Investig N Drugs"},{"key":"10.1016\/j.ejca.2024.115152_bib113","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000571","article-title":"Amelanotic melanoma","author":"Gong","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib114","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2018.04.045","article-title":"Clinically amelanotic or hypomelanotic melanoma: anatomic distribution, risk factors, and survival","volume":"79","author":"Wee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Whiteman","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib116","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib117","series-title":"WHO Classification of Skin Tumours","first-page":"72","article-title":"The genomic landscape of melanoma","author":"Bastian","year":"2018"},{"key":"10.1016\/j.ejca.2024.115152_bib118","doi-asserted-by":"crossref","unstructured":"F.J. Hilke T. Sinnberg A. Gschwind H. Niessner G. Demidov T. Amaral\u00a0et al. Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients Cancers 12 2020.","DOI":"10.3390\/cancers12092359"},{"key":"10.1016\/j.ejca.2024.115152_bib119","unstructured":"Genomic Classification of Cutaneous Melanoma Cell 161 2015 1681 1696."},{"key":"10.1016\/j.ejca.2024.115152_bib120","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib121","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2217\/fon-2023-0414","article-title":"COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB\/IIC BRAF V600-mutated melanoma","volume":"19","author":"van Akkooi","year":"2023","journal-title":"Future Oncol (Lond, Engl)"},{"key":"10.1016\/j.ejca.2024.115152_bib122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.phrs.2016.03.007","article-title":"Targeting mutant NRAS signaling pathways in melanoma","volume":"107","author":"Vu","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejca.2024.115152_bib123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2024.115152_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2024.115152_bib125","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1186\/s12885-015-1811-y","article-title":"Clinical detection and categorization of uncommon and concomitant mutations involving BRAF","volume":"15","author":"Zheng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib126","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib127","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","article-title":"The current state of molecular testing in the BRAF-mutated melanoma landscape","volume":"7","author":"Vanni","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ejca.2024.115152_bib128","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.115152_bib131","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib132","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib133","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"key":"10.1016\/j.ejca.2024.115152_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100520","article-title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","volume":"7","author":"Janku","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.115152_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113312","article-title":"A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)","volume":"193","author":"Kim","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib136","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.pathol.2018.08.004","article-title":"Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases","volume":"50","author":"Leichsenring","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.ejca.2024.115152_bib137","first-page":"1387","article-title":"NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications","volume":"18","author":"Forschner","year":"2020","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2024.115152_bib138","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib139","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib140","article-title":"Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib141","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib142","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.115152_bib143","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study","volume":"7","author":"Forschner","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib144","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"key":"10.1016\/j.ejca.2024.115152_bib145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2024.115152_bib146","first-page":"39","volume":"28","author":"Mahoney","year":"2014"},{"key":"10.1016\/j.ejca.2024.115152_bib147","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2016-0013","article-title":"PD-L1 in melanoma: facts and myths","volume":"3","author":"Mandal\u00e0","year":"2016","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.ejca.2024.115152_bib148","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib149","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115152_bib150","unstructured":"E.M.A. Opdualag: EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdualag2024."},{"key":"10.1016\/j.ejca.2024.115152_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104774","article-title":"Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG\/TRIM","volume":"96","author":"Placke","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2024.115152_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113476","article-title":"PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma","volume":"198","author":"Ellebaek","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.10.016","article-title":"Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients","volume":"143","author":"Gambichler","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","article-title":"Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)","volume":"182","author":"Amaral","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.115152_bib156","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2023.01.002","article-title":"Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I\u2013IIA cutaneous melanoma","volume":"182","author":"Meyer","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib157","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cam4.2128","article-title":"Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma","volume":"8","author":"Keller","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.115152_bib158","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1245\/s10434-021-11099-3","article-title":"Genomic expression profiling in melanoma and the road to clinical practice","volume":"29","author":"Sabel","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib159","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.jaad.2018.11.063","article-title":"Use of a prognostic gene expression profile test for T1 cutaneous melanoma: will it help or harm patients?","volume":"80","author":"Marchetti","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib160","article-title":"31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a SEER collaboration","volume":"7","author":"Bailey","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib161","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010019","article-title":"Promising and minimally invasive biomarkers: targeting melanoma","volume":"13","author":"Spiliopoulou","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2024.115152_bib162","doi-asserted-by":"crossref","first-page":"S904","DOI":"10.1016\/j.annonc.2022.07.914","article-title":"788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)","volume":"33","author":"Long","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib163","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","article-title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","volume":"158","author":"Gracie","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib164","doi-asserted-by":"crossref","unstructured":"Lee R.J., Rothwell D.G., Chow S., Shaw H.M., Turajlic S., Smith N., et al. CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9587"},{"key":"10.1016\/j.ejca.2024.115152_bib165","doi-asserted-by":"crossref","unstructured":"Lee R.J., Rothwell D.G., Jackson R., Smith N., Wong S.Q., Kelso N., et al. DETECTION phase II\/III trial: Circulating tumor DNA-guided therapy for stage IIB\/C melanoma after surgical resection. 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9603"},{"key":"10.1016\/j.ejca.2024.115152_bib166","first-page":"210","article-title":"Update in genetic susceptibility in melanoma","volume":"3","author":"Potrony","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2024.115152_bib167","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5826\/dpc.0901a03","article-title":"Familial melanoma: diagnostic and management implications","volume":"9","author":"Rossi","year":"2019","journal-title":"Dermatol Pr Concept"},{"key":"10.1016\/j.ejca.2024.115152_bib168","doi-asserted-by":"crossref","first-page":"adv00138","DOI":"10.2340\/00015555-3493","article-title":"Melanoma genomics","volume":"100","author":"Newton-Bishop","year":"2020","journal-title":"Acta Derm-Venereol"},{"key":"10.1016\/j.ejca.2024.115152_bib169","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/jdv.19461","article-title":"High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: a multicentre cohort from the MelaNostrum Consortium","volume":"37","author":"Pellegrini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ejca.2024.115152_bib170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jmg.2006.043802","article-title":"Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents","volume":"44","author":"Goldstein","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.ejca.2024.115152_bib171","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10555-017-9661-5","article-title":"Identification, genetic testing, and management of hereditary melanoma","volume":"36","author":"Leachman","year":"2017","journal-title":"Cancer Metastas-- Rev"},{"key":"10.1016\/j.ejca.2024.115152_bib172","first-page":"34","article-title":"Genetic testing for familial melanoma","volume":"159","author":"Primiero","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.ejca.2024.115152_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100525","article-title":"Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup","volume":"7","author":"Bruno","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.115152_bib174","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2008.17.4110","article-title":"Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study","volume":"27","author":"Stensheim","year":"2009","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10552-005-0281-y","article-title":"Pregnancy history and incidence of melanoma in women: a pooled analysis","volume":"17","author":"Karagas","year":"2006","journal-title":"Cancer causes Control: CCC"},{"key":"10.1016\/j.ejca.2024.115152_bib176","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10552-008-9110-4","article-title":"Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues","volume":"19","author":"Lens","year":"2008","journal-title":"Cancer causes Control: CCC"},{"key":"10.1016\/j.ejca.2024.115152_bib177","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.20925","article-title":"Malignant melanoma in pregnancy. A population-based evaluation","volume":"103","author":"O'Meara","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib178","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.2004.02.096","article-title":"Effect of pregnancy on survival in women with cutaneous malignant melanoma","volume":"22","author":"Lens","year":"2004","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib179","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejca.2022.02.016","article-title":"Melanoma in pregnancy: diagnosis and management in early-stage and advanced disease","volume":"166","author":"Carter","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1753495X17695001","article-title":"Melanoma in pregnancy","volume":"10","author":"Still","year":"2017","journal-title":"Obstet Med"},{"key":"10.1016\/j.ejca.2024.115152_bib181","series-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","article-title":"Menopausal hormone therapy and risk of melanoma: A nationwide register-based study in Finland","author":"Botteri","year":"2019"},{"key":"10.1016\/j.ejca.2024.115152_bib182","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archdermatol.2010.2","article-title":"Increased risk of second primary cancers after a diagnosis of melanoma","volume":"146","author":"Bradford","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib183","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/CMR.0000000000000395","article-title":"Multiple primary melanoma: a single centre retrospective review","volume":"27","author":"Menzies","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.115152_bib184","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","article-title":"Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","volume":"28","author":"Dreno","year":"2017","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"key":"10.1016\/j.ejca.2024.115152_bib185","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2014.55.0590","article-title":"Safety and management of new primary melanomas during receipt of BRAF inhibitors","volume":"32","author":"Perier-Muzet","year":"2014","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib186","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib187","first-page":"18","article-title":"A global review of melanoma follow-up guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J Clin aesthetic Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib188","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jdv.17086","article-title":"Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries","volume":"35","author":"Kandolf-Sekulovic","year":"2021","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ejca.2024.115152_bib189","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.294.13.1647","article-title":"Clinicopathological features of and risk factors for multiple primary melanomas","volume":"294","author":"Ferrone","year":"2005","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2024.115152_bib190","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2015.06.059","article-title":"Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011","volume":"73","author":"Moore","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib191","article-title":"Assessing the potential for patient-led surveillance after treatment of localized melanoma (MEL-SELF): a pilot randomized clinical trial","author":"Ackermann","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib192","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1055-9965.EPI-12-1346","article-title":"Dysplastic nevi and melanoma","volume":"22","author":"Goldstein","year":"2013","journal-title":"Cancer Epidemiol, Biomark Prev: a Publ Am Assoc Cancer Res, cosponsored Am Soc Prev Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib193","first-page":"204","article-title":"Serum levels of S-100b protein after four years follow-up of patients with melanoma","volume":"9","author":"Zissimopoulos","year":"2006","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.ejca.2024.115152_bib194","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejso.2011.12.005","article-title":"The current status of S-100B as a biomarker in melanoma","volume":"38","author":"Kruijff","year":"2012","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib195","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1245\/s10434-010-1085-1","article-title":"Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival","volume":"17","author":"Kruijff","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115152_bib196","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.115152_bib197","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clindermatol.2009.06.013","article-title":"Incisional biopsy and melanoma prognosis: facts and controversies","volume":"28","author":"Pflugfelder","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib198","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2017.07.051","article-title":"Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: a comparative cohort study","volume":"85","author":"Ribero","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115152_bib199","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","article-title":"Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study","volume":"75","author":"Podlipnik","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.05.076","article-title":"Diagnostic accuracy of imaging studies for initial staging of T2b-T4b melanoma patients. A cross-sectional study","author":"Riquelme-Mc Loughlin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.115152_bib201","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/bjd.16833","article-title":"Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma","volume":"180","author":"Podlipnik","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T07:13:12Z","timestamp":1740294792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":201,"alternative-id":["S0959804924017593"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115152","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115153","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115152"}}